Krishna Yeshwant Sells 18,072 Shares of Foundation Medicine, Inc. (NASDAQ:FMI) Stock
Foundation Medicine, Inc. (NASDAQ:FMI) Director Krishna Yeshwant sold 18,072 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $36.85, for a total value of $665,953.20. Following the completion of the sale, the director now directly owns 5,786 shares in the company, valued at $213,214.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Foundation Medicine, Inc. (NASDAQ:FMI) traded up 4.03% on Tuesday, hitting $40.00. The stock had a trading volume of 256,900 shares. Foundation Medicine, Inc. has a 12 month low of $17.10 and a 12 month high of $43.15. The company’s 50 day moving average price is $38.65 and its 200-day moving average price is $32.76. The company’s market cap is $1.44 billion.
Foundation Medicine (NASDAQ:FMI) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.08) by $0.16. Foundation Medicine had a negative net margin of 131.79% and a negative return on equity of 109.63%. The company had revenue of $35 million during the quarter, compared to analysts’ expectations of $34.94 million. During the same quarter in the prior year, the business posted ($0.84) earnings per share. The company’s revenue was up 23.9% compared to the same quarter last year. On average, analysts expect that Foundation Medicine, Inc. will post ($4.59) earnings per share for the current year.
FMI has been the topic of several analyst reports. BTIG Research raised Foundation Medicine from a “neutral” rating to a “buy” rating and set a $39.00 target price on the stock in a report on Monday, May 15th. BidaskClub raised Foundation Medicine from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Zacks Investment Research raised Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, ValuEngine raised Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $29.50.
Several hedge funds have recently bought and sold shares of the company. Pioneer Investment Management Inc. acquired a new stake in Foundation Medicine during the first quarter worth $10,502,000. Alliancebernstein L.P. boosted its stake in Foundation Medicine by 38.7% in the first quarter. Alliancebernstein L.P. now owns 788,860 shares of the company’s stock worth $25,441,000 after buying an additional 220,236 shares during the last quarter. Adalta Capital Management LLC acquired a new stake in Foundation Medicine during the first quarter worth $4,056,000. Geode Capital Management LLC boosted its stake in Foundation Medicine by 27.2% in the first quarter. Geode Capital Management LLC now owns 140,182 shares of the company’s stock worth $4,520,000 after buying an additional 29,984 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Foundation Medicine during the fourth quarter worth $552,000. 30.91% of the stock is owned by hedge funds and other institutional investors.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.